PTX35-001 A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients With Advanced Solid Tumors Refractory to Standard of Care
Latest Information Update: 15 Mar 2024
At a glance
- Drugs PTX 35 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Pelican Therapeutics; Scorpius Holdings
- 06 Feb 2024 According to a NightHawk Biosciences media release, the NightHawk Biosciences has changed its name to Scorpius Holdings.
- 20 Nov 2023 According to a NightHawk Biosciences media release, PTX-35 expense decreased by $0.5 million primarily due to the discontinued development of PTX-35 in the third quarter of 2022.
- 20 Nov 2023 Status changed from active, no longer recruiting to discontinued, according to a NightHawk Biosciences media release.